ALSO NOTED: GSK to co-develop cancer therapy; Singulair approved for new use; Teva gets FDA nod; and much more...

> GlaxoSmithKline has exercised an option to help develop and market a new cancer therapy with Human Genome Sciences. Story

> The FDA has approved Merck's Singulair for indoor allergy uses. Release

> The FDA has given tentative approval to Teva's ANDA for Granisetron HCl Injection, 1 mg/mL single dose vials and Granisetron HCl Injection, 4 mg/4mL in multi-dose vials. Story

> The National Cancer Institute says that an ambitious program of earlier detection, better therapies and controls on tobacco can stop lung cancer by 2015. Report

> Dyax and Merck have inked a licensing deal for the discovery of therapeutic antibodies and peptides. Release

> Novartis has signed an agreement with SeBo of Germany to acquire the global rights for a novel oral phosphate binder in development for the treatment of elevated serum phosphate levels in late- or end-stage renal disease patients. Release

And Finally… The death rate from heart disease in New York is among the highest in the country, but health officials are at a loss to explain why. Article

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.